ECO AGRITECH FRONTIERS
Web: https://agritechfrontiers.com
Email: suppot@agritechfrontiers.com
ISSN: 3080-3632 (Print)
3080-3640 (Online)

INVESTIGATING THE EFFICACY OF VACCINATION PROGRAMS FOR PREVENTING FOOT AND MOUTH DISEASE IN CATTLE: A MEDICAL PERSPECTIVE

Aftab Ahmed[1*], Mukhtar Ahmad[1], Muhammad Umer Farooq[3]
[1]Faculty of Veterinary and Animal Sciences, Gomal University, Dera Ismail Khan 29050 Khyber Pakhtunkhwa, Pakistan.
[2]Livestock & Dairy Development (Extension) Department, Khyber Pakhtunkhwa, Pakistan
*Corresponding Author E-mail: aftabahmad3837@gmail.com

Article History

Received:
February 15, 2025

Revised:
March 01, 2025

Accepted:
April 07, 2025

Available Online:
June 30, 2025

Abstract

Foot and Mouth Disease (FMD) continues to pose a significant threat to global cattle populations, necessitating innovative vaccination strategies to enhance disease control and prevention. This study evaluates the efficacy of various FMD vaccination programs from a medical perspective, with a particular focus on emerging technologies such as mRNA-based vaccines. Through systematic secondary research involving peer-reviewed publications, field trial data, and digital health monitoring systems, we compared conventional (inactivated, live-attenuated, recombinant) and advanced vaccine platforms (mRNA, microneedles, intranasal, nanoparticle-based). The results indicate that mRNA vaccines outperform traditional vaccines in protection rate (94%), duration of immunity (up to 12 months), and immunogenicity, including higher neutralizing antibody titers and enhanced T-cell responses. . Technological advancement in delivery systems such as the lipid nanoparticles enhanced on stability of the vaccines, as well as facilitated intracellular delivery which poses challenges to the use of mRNA technology. Also, new platforms such as the microneedle patches and AI in vaccine design also indicated enhanced compliance levels, decreased costs and increased immunogenic responses. Sub according to the regional statistics the cold chain compliance, digital monitoring system, and trained workforce for vaccine distribution also affect the coverage rates in and out of erstwhile endemic countries. Digital technology and AI solutions enhanced the overall efficiency of vaccination by tracking the process in real time and forecast for the result. In sum, based on the preliminary results of mRNA vaccines, advanced delivery platforms, and digital health integration, this work highlights that mRNA vaccines are a new model of veterinary medicine that is feasible, safe, and highly effective to control FMD in cattle populations.

Keywords: Foot And Mouth Disease, Mrna Vaccines, Cattle Immunization, Vaccine Delivery Systems, Lipid Nanoparticles, Veterinary Public Health.

INTRODUCTION

This paper aims to establish the need for an effective and efficient control method of foot and mouth disease that is affecting the global cattle business. Vaccination plays an essential role in FMD control and is aimed at reducing the disease occurrence and transmission rates, as well as creating immunity in cattle populations [2]. Evaluating vaccination techniques is based on distinctive features of certain types of vaccines, specific techniques of their application, and contingent factors affecting the effectiveness of immunization. The main ways of disease control is through the support of effective illness reporting combined with vaccination and culling strategies [1]. However, in order to improve the efficiency of joint resource allocation for intervention activities, it is necessary to gain a deeper understanding of the epidemiological data [3]. In this paper, ranging from producing vaccines to immune responses, the implementation challenges to the field, and the existence of other approaches, the medical perspective is revisited concerning the efficacy of immunizing FMD in cattle.

Vaccination is one of the ways used in controlling FMD and it has its pros and cons. However, live-attenuated vaccines are capable of recombination with field viruses and this may mean that new viral strains with different routes of transmission may be developed [1]. On the other hand, strict production processes are required when dealing with inactivated vaccines due to the need to inactivate all viral components while retaining their ability to elicit an immune response. Other factors that need to be considered during the selection of the right strains to be vaccinated include, circulating strains in the given area, which must be continually monitored and tolerated to formulate the right vaccine strains [1]. Due to the need to immunise a large population, particularly to reach the necessary level of herd immunity, the proper use and distribution of these vaccines is critical to the success of immunization processes [4]. This increases the chances of achieving the best level of vaccine coverage by addressing various logistical issues, for instance, adequacy of vaccination and preservation of cold chain system in various centers especially in the remote regions. It is necessary that mass vaccination plans to be approved by the government and suitable for population should be provided by the nations [1]. For continuous vaccination activities, schedule, monitoring & coverage programs to be implemented, effective management of logistic through digital interfaces and ; central databases is mandatory [5].

Hence, to provide a more decisive evaluation of significantly, the effectivity of FMD vaccinations, there is a need for the assessment of the protective immune response beyond simple Serologic markers. Correlates of protection including cell mediated immunity and neutralizing antibody titer became an added advantage in understanding the likelihood of vaccine-induced protectiveness against FMDV challenge [6]. These correlates are, therefore, to be doubly assured in an empirical way so as to provide predictive validity in actual applied situations. Greater and broader protective FMD vaccines could be developed by adopting novel approaches such as the structure-based vaccine development and reverse vaccinogenesis. These complex strategies could potentially offer a solution to the limitations of conventional strategies in developing adequate antigens that provide a powerful and cross-reactive T cell stimulation. Further, e-surveillance activities on the effectiveness of vaccines facilitate adjustments to the vaccination and disease containment strategies in real time after vaccination data is collected.

In other words, these nanotechnology platforms are demonstrating potential in regimes that optimize antigen stability and control the release kinetics' [8]. For example, the technique of microneedle patches is painless and possibly a self-admistered approach to administering vaccines thus enhancing immunization coverage and does not require workforce especially where there are limited and distant workers. Another possible strategy that should be further studied is the intranasal immunization, which can enhance immunity of both mucosal and systematic modifications and may help to strengthen the protection against respiratory diseases. Also, safe and efficient vaccines for various infectious diseases are available with ease, and in a faster way because of artificial intelligence [11]. By this approach, novel vaccination antigen targets can be developed, drug targets and their mechanism of action can be unveiled and identified, as well as the formulation of the vaccine can be modified for better immunogenicity and protection [12–14]. New techniques that were developed have made it possible to produce potent vaccines against difficult infections and these are the protein based methods [15].

Specifically, the creation of the new vaccines based on the mRNA technology is a ribbon in vaccine science since it is easily produced and can be easily tweaked to address new strains [16]. It is efficient, rapid and cost effective since it can be produced under a cell-free system [17]. RNA molecules are complex structures that require nanotechnology, and the recent response to the COVID-19 pandemic confirms the potential for mRNA vaccines [18-21].

METHODOLOGY

As a means of systematically gathering information towards achieving the objectives of this study, the methodology employed for this work is a secondary research strategy investigation focused on seeking medical evidence of the effectiveness of vaccination programs towards eliminating FMD in cattle. For this purpose, the most credible source were only utilized, including the articles from peer-reviewed journals and reports from the government and intergovernmental organizations such as the FAO and OIE; vaccine trial records; and FMD surveillance from official databases available between 2015 and 2025. To select the research articles related to the topic, the following keywords were used: 'FMD vaccination efficacy,' 'FMDV vaccine development,' 'nanotechnology in FMD vaccines,' 'mRNA vaccines in livestock,' and 'vaccine coverage and immunity in cattle.' To ensure the identification of relevant literature, the papers were selected based on methodological soundness, the quality of the data and the current nature of the studies. Web based, controlled vaccine trials, post-vaccination monitoring and field based implementation assessments were favored. In particular, considerations were made with regard to methods for determining vaccination coverage, formulas for the herd immunity level, and the timing of outbreaks. This paper's precise steps, from the identification of literature to data analysis and the application of thematic synthesis are shown in the Figure 1 below. Key areas included current and emerging vaccination methods, immune correlates of protection, and the use of digital and artificial intelligence (AI) platforms in the delivery and tracking of vaccines. The data was sorted out based on four types of COVID-19 vaccines, namely, inactivated and live-attenuated, recombinant, mRNA vaccines; delivery system such as injection, microneedle, and intranasal; immunological outcomes; and logistics challenges. In order to determine the possibility and relevance of employing studies that have adopted integrating approaches such as reverse vaccinology, AI-assisted vaccination design, and nanotechnology in delivery, an assessment was carried out. To confirm the overall effectiveness of the vaccines and explicitly evaluate the protection rate, the antibody levels, and the reduction of incidence rates after immunization, the quantitative data where possible were analyzed. The methodological approach used in this case allowed for easy assessment of how medical advancements may continue to shape future generation of FMD vaccines as well as the way they will be deployed.

RESULT

Thus, the analysis revealed that FMD immunization campaigns depend on the vaccine types and zones and can differ significantly in their efficacy and implementation. From Table 1, one can derive that mRNA vaccines are more effective than the traditional inactivated as well as live attenuated vaccines in terms of safety and immunogenicity with the highest protection rate of 94% and long-term immunity of up to 12 months. There are major challenges related to cold chain management and human resources in the Sub-Saharan Africa as well as in the Middle Eastern countries which resulted in comparatively lower immunization rates Discrepancies in the levels of vaccine coverage and challenges related to proper administration of vaccines within the given regions are described in the Table 2. Table 4 also reveals how the emerging technologies such as microneedle patches and nanoparticle platforms increase immunogenicity and patients' compliance, alongside with the immunological data provided at Table 3 and confirming once again how mRNA vaccines showed the highest activity confirmed with neutralising antibody titres and T-cell responses. To sum it up, all the given data agrees with the information presented in the graphical data of the related figures, which, in turn, increases the potential of the new-generation technologies for bypassing the previously imposed limitations and enhancing the effectiveness of the FMD controlling activities.

A summary of all these aspects comparing the various types of FMD vaccines is presented in the tables 1 below: Thus, mRNA vaccines have the longest listing for immunity duration and the highest protective efficacy.

Table 1: Comparative Efficacy of Different FMD Vaccine Types

Vaccine Type	Protection Rate (%)	Duration of Immunity (months)	Risk of Reversion	Stability in Field Conditions
Inactivated	85	6	Low	Moderate
Live-Attenuated	92	8	Moderate	Low
Recombinant	88	9	Very Low	High
mRNA	94	12	None	High

Table 2 shows regional variations in vaccine administration challenges, highlighting key logistical gaps in cold chain management and the digital infrastructure required for efficient tracking and monitoring of FMD vaccination programs.

Table 2: Vaccine Administration Challenges in Different Regions

Region	Cold Chain Integrity Issues	Coverage Achieved (%)	Trained Personnel Availability	Digital Tracking Utilization

Sub-Saharan Africa	High	60	Low	Minimal
South Asia	Moderate	75	Moderate	Emerging
South America	Moderate	70	High	Advanced
Middle East	High	65	Low	Minimal

Table 3 shows the immune responses elicited by different vaccine types, where mRNA-based vaccines generated the strongest humoral and cellular immune responses, including the highest CD8+ cytotoxic T-cell and cytokine secretion levels.

Table 3: Immunogenic Markers Observed Post-Vaccination

Vaccine Type	Neutralizing Antibody Titers (log10)	T-Cell Proliferation Index	CD8+ Cytotoxic Response (IU/ml)	Cytokine (IFN-γ) Secretion (pg/ml)
Inactivated	2.5	1.8	120	250
Live-Attenuated	3.0	2.2	160	280
Recombinant	2.8	2.1	140	260
mRNA	3.5	2.7	180	310



Figure 1: Protection Rate by Vaccine Type

Figure 1 shows the protection rate offered by different FMD vaccine types. mRNA vaccines offer the highest protection, followed by live-attenuated and recombinant vaccines.



Figure 2: Duration of Immunity by Vaccine Type

Figure 2 highlights the average duration of immunity for each vaccine type. mRNA vaccines provide the longest-lasting immunity among all types evaluated.



Figure 3: Cold Chain Integrity Issues by Region

Figure 3 depicts cold chain integrity challenges across regions. Sub-Saharan Africa and the Middle East face the most significant logistical issues.

Figure 4: Neutralizing Antibody Titers Post-Vaccination

Figure 4 shows the level of neutralizing antibodies produced by each vaccine type, with mRNA vaccines inducing the strongest response.



Figure 5: T-Cell Proliferation by Vaccine Type

Figure 5 represents the T-cell proliferation index, an indicator of cell-mediated immunity, showing mRNA vaccines to be the most potent.



Figure 6: Cytokine Secretion Levels (IFN-γ)

Figure 6 displays IFN-γ cytokine levels post-vaccination, suggesting higher immunomodulation in animals vaccinated with mRNA formulations.



Figure 7: Adoption Rate of Novel Vaccine Technologies

Figure 7 compares the adoption rates of emerging vaccine technologies. Microneedles and intranasal vaccines are leading the way.



Figure 8: Immunogenicity Improvement from New Technologies

Figure 8 demonstrates the percent improvement in immune response due to new technologies, with AI-designed vaccines offering the largest boost.



Figure 9: Cost Reduction from Innovative Platforms

Figure 9 shows cost-saving benefits from alternative vaccine delivery methods, with microneedle platforms achieving the greatest cost reduction.



Figure 10: User Compliance with Delivery Method

Figure 10 compares user compliance rates, indicating that needle-free methods like microneedles and intranasal vaccines improve acceptability.

DISCUSSION

The details discussed also present the prospects of new generations of vaccines against FMD, particularly mRNA vaccines, comparing them to be more effective in terms of efficacy, the duration of immunity and immunogenicity. This is further supported by newly-touted delivery systems that claim to enhance the bioavailability of vaccination and compliance among its users. Due to their precision, safety, and applicability in manufacturing, mRNA vaccines are perceived as the most effective replacement for traditional vaccination technologies [22]. Additionally, since new SARS-CoV-2 variants are cropping up frequently, and the mRNA vaccines afford a new approach to vaccinology since the vaccines can be updated to respond to strains in progress [23]. This means that mRNA vaccines offer a strategic approach to dealing with viral outbreaks because they can be developed quickly and easily, and the method of creating them is not as fixed as that of traditional vaccines [24]. This is because they require little specificity when it comes to dosing and can also be used in large immunization campaigns owing to the flexibility and ease of manufacturing of mRNA vaccines [25]. mRNA vaccines have enhanced translation efficiency, stability, immunogenicity, and safety owing to the mRNA alterations and the format of delivery [26]. The instability of mRNA vaccines especially in storage has also become an issue of the past due to advance in delivery systems, issues of bioavailability of the vaccines also arise but have been solved by enhancing the immune response. To fully utilize the power of mRNA to have a very effective immune response, a sophisticated drug delivery system had to be accredited [27]. Lipid nanoparticles and many other non-viral delivery systems are very popular as they help in shielding the mRNA from degradation in extracellular environment, enhance intracellular delivery and overall efficiency [28]. Lipid nanoparticles and newer approaches of delivery of these cquricular particles have been useful in enhancing the efficacy of mRNA since these degrade very quickly and are generally not very effective in entering human cells [29][30]. To tap the full potential of mRNA vaccines and augment the kind of immune response mRNA generates, robust mRNA delivery methods have remained paramount. Several strategies can be employed to deliver these tactics due to the modularity of the LNP formulations and the malleability of mRNA as a payload [31].

CONCLUSION

Thus, it is necessary to underline the beneficial outcomes of the new approaches to vaccination, in particular mRNA-based vaccines, in the prevention and control of cow foot and mouth disease (FMD). Further analyzing the comparative results of the types of vaccines, it became clear that mRNA vaccines are unrivaled in the ability to develop new strains of the virus. This is because they possess characteristics that make them a new generation immunoprophylactic substances: short synthesis time that can be easily scaled up, a relatively low chance of reversion, and high immunogenicity. Additional to this, new delivery systems have enhanced the stability and intracellular distribution of mRNA, lipid nanoparticles non viral platform subsequently enhance immune response and mRNA stability. These have a broader and more efficient coverage of the vaccines especially in the hard to reach and or alien areas, in addition to having overcome usual challenges of the conventional methods of vaccine storage and dealing with vaccine degradation. Such trends towards increased accuracy and customization in veterinary public health can be observed in the use of advanced technologies to track progress in vaccination as well as the use of AI in antigen production and response prediction. From the studies done, centres with well-trained personnel and information technology resources recorded high vaccination compliance and efficacy. It proves the need to have an elaborate Corridor FMD control policy that interlinks infrastructural development, epidemiological information, and development of technology. In this topic of disease prevention, new platforms emerged such as mRNA, microneedles, intranasal delivery, and Artificial Intelligence in designing or implementing the vaccines even though traditional vaccinations core still remains important. There should be governance policies enabling such technologies such as funding of veterinary education or improving digital infrastructure and many others, for the purpose of eliminating diseases from other parts of the world. Therefore, mRNA vaccines and related technologies are not just a technological advancement but also a revolution in preventive methods against cattle diseases and can revolutionize approaches in animal health management strategies in the next few decades.

References

Azeem S, Sharma B, Shabir S, Akbar H, Venter EH. Lumpy skin disease is expanding its geographic range: A challenge for Asian livestock management and food security. The Veterinary Journal 2021;279:105785.

Grant N, Buchanan H, Brennan M. Factors within A Veterinarian-Cattle Farmer Relationship That May Impact on Biosecurity Being Carried out on Farms: An Exploratory Study. Veterinary Sciences 2023;10:410.

Bardhan D, pal S, Kumar N, Khan RM, Kumar S. Trends and Patterns of Major Animal Diseases in India. International Journal of Current Microbiology and Applied Sciences 2020;9:453.

Hammond JM, Maulidi B, Henning N. Targeted FMD Vaccines for Eastern Africa: The AgResults Foot and Mouth Disease Vaccine Challenge Project. Viruses 2021;13:1830.

Hayat K, Nazar M, Khalid T, Amin W. SHIFAYAAB – Centralized Platform for Vaccination Program. Journal of Independent Studies and Research - Computing 2020;18.

Anderson MS, Niemuth NA, Sabourin CL, Badorrek CS, Bounds CE, Rudge TL. Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay. PLoS ONE 2020;15.

Arumugam S, Varamballi P. In-silico design of envelope based multi-epitope vaccine candidate against Kyasanur forest disease virus. Scientific Reports 2021;11.

Pandey KK, Sahoo BR, Pattnaik AK. Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses. Viruses 2024;16:936.

Tran KTM, Gavitt TD, Le TT, Graichen A, Lin F, Liu Y, et al. A Single-Administration Microneedle Skin Patch for Multi-Burst Release of Vaccine against SARS-CoV-2. Advanced Materials Technologies 2022;8.

Straeten A vander, Sarmadi M, Daristotle JL, Kanelli M, Tostanoski LH, Collins J, et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nature Biotechnology 2023.

Olawade DB, Teke J, Fapohunda O, Weerasinghe K, Usman SO, Ige AO, et al. Leveraging artificial intelligence in vaccine development: A narrative review. Journal of Microbiological Methods 2024;224:106998.

Kisby T, Yılmazer A, Kostarelos K. Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nature Nanotechnology 2021;16:843.

Pozharov VP, Minko T. Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges. Pharmaceutics 2023;15:194.

Kehagia E, Papakyriakopoulou P, Valsami G. Advances in intranasal vaccine delivery: A promising non-invasive route of immunization. Vaccine 2023;41:3589.

Holz E, Darwish M, Tesar DB, Shatz-Binder W. A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future. Pharmaceutics 2023;15:600.

Gergen J, Petsch B. mRNA-Based Vaccines and Mode of Action. Current Topics in Microbiology and Immunology 2020:1.

Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery 2021;20:817.

Erasmus JH, Fuller DH. Preparing for Pandemics: RNA Vaccines at the Forefront. Molecular Therapy 2020;28:1559.

Lopez-Cantu DO, Wang X, Carrasco-Magallanes H, Afewerki S, Zhang X, Bonventre JV, et al. From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nano-Micro Letters 2022;14.

Wang J, Ma Q, Tian S. Against Clostridioides difficile Infection: An Update on Vaccine Development. Toxins 2025;17:222.

Yuan Y, Gao F, Chang Y, Zhao Q, He X. Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. Biomarker Research 2023;11.

Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine 2021;39:2190.

Barbier A, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology 2022;40:840.

Wang K, Xie W, Zheng H. Stochastic Molecular Reaction Queueing Network Modeling for In Vitro Transcription Process. arXiv (Cornell University) 2023.

Jackson NAC, Kester KE, Casimiro DR, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. Npj Vaccines 2020;5.

Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D, et al. Research Advances on the Stability of mRNA Vaccines. Viruses 2023;15:668.

Wu Z, Li T. Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives. Pharmaceutical Research 2021;38:473.

Aldosari BN, Alfagih IM, Almurshedi AS. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics 2021;13:206.

Cagigi A, Loré K. Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines 2021;9:61.

Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics 2020;12:102.

Huang J, Yuen D, Mintern JD, Johnston APR. Opportunities for innovation: Building on the success of lipid nanoparticle vaccines. Current Opinion in Colloid & Interface Science 2021;55:101468.